Open AccessFeasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
Author(s) -
Sunami Kuniko,
Ichikawa Hitoshi,
Kubo Takashi,
Kato Mamoru,
Fujiwara Yutaka,
Shimomura Akihiko,
Koyama Takafumi,
Kakishima Hiroki,
Kitami Mayuko,
Matsushita Hiromichi,
Furukawa Eisaku,
Narushima Daichi,
Nagai Momoko,
Taniguchi Hirokazu,
Motoi Noriko,
Sekine Shigeki,
Maeshima Akiko,
Mori Taisuke,
Watanabe Reiko,
Yoshida Masayuki,
Yoshida Akihiko,
Yoshida Hiroshi,
Satomi Kaishi,
Sukeda Aoi,
Hashimoto Taiki,
Shimizu Toshio,
Iwasa Satoru,
Yonemori Kan,
Kato Ken,
Morizane Chigusa,
Ogawa Chitose,
Tanabe Noriko,
Sugano Kokichi,
Hiraoka Nobuyoshi,
Tamura Kenji,
Yoshida Teruhiko,
Fujiwara Yasuhiro,
Ochiai Atsushi,
Yamamoto Noboru,
Kohno Takashi
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13969
Subject(s) - medicine , clinical trial , oncology , clinical practice , multiplex , cancer , gene , bioinformatics , genetics , family medicine , biology
Next‐generation sequencing ( NGS ) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital‐based prospective study ( TOP ‐ GEAR project, 2nd stage) to investigate the feasibility and utility of NGS ‐based analysis of 114 cancer‐associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data were obtained for 187 cases (81.3%), 111 (59.4%) of which harbored actionable gene aberrations according to the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment (Edition 1.0) issued by 3 major Japanese cancer‐related societies. Twenty‐five (13.3%) cases have since received molecular‐targeted therapy according to their gene aberrations. These results indicate the utility of tumor‐profiling multiplex gene panel testing in a clinical setting in Japan. This study is registered with UMIN Clinical Trials Registry ( UMIN 000011141).